A Study to Learn About the Study Medicine Called Infliximab (Genetical Recombination)[Infliximab Biosimilar 3] in People With Rheumatoid Arthritis, Ulcerative Colitis, Crohn's Disease, or Psoriasis : Infliximab-Pfizer Biosimilar Post-Marketing Database Study
The purpose of this study is to learn about the safety of the safety of the study medicine called infliximab for the possible treatment of rheumatoid arthritis (RA), ulcerative colitis (UC, Crohn's disease, or psoriasis.RA is a kind of joint disease that causes pain and swelling.UC causes inflammation and sores (also called ulcers), in the lining of the rectum and colon.Chron's disease is a disease that lasts for a long time and causes severe irritation in your digestive tract.Psoriasis is a skin disease that gives you a dry, scaly rash.The study includes patient's data from the database who:Have at least 90 days of look-back periodHave any of these diseases (RA, UC, Crohn's disease, or Psoriasis) in the 90-day look back periodAre 15 years of age or older at the time of first dosingAll the patient's data included in this study would have received infliximab as intravenous (into veins) injection..
| Medienart: |
|
|---|
Klinische Studie| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
ClinicalTrials.gov - (2024) vom: 05. März Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
610 |
|---|
| Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: April 3, 2023, Last downloaded: ClinicalTrials.gov processed this data on March 13, 2024, Last updated: March 13, 2024 |
|---|
| Study ID: |
NCT05796245 |
|---|---|
| Veröffentlichungen zur Studie: |
|
| fisyears: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
CTG000058882 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | CTG000058882 | ||
| 003 | DE-627 | ||
| 005 | 20240313010413.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240313s2024 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)CTG000058882 | ||
| 035 | |a (UBBS_Klinische_Studien)NCT05796245 | ||
| 035 | |a (UBBS_Klinische_Studien)B5371010 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a A Study to Learn About the Study Medicine Called Infliximab (Genetical Recombination)[Infliximab Biosimilar 3] in People With Rheumatoid Arthritis, Ulcerative Colitis, Crohn's Disease, or Psoriasis |b Infliximab-Pfizer Biosimilar Post-Marketing Database Study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: April 3, 2023, Last downloaded: ClinicalTrials.gov processed this data on March 13, 2024, Last updated: March 13, 2024 | ||
| 520 | |a The purpose of this study is to learn about the safety of the safety of the study medicine called infliximab for the possible treatment of rheumatoid arthritis (RA), ulcerative colitis (UC, Crohn's disease, or psoriasis.RA is a kind of joint disease that causes pain and swelling.UC causes inflammation and sores (also called ulcers), in the lining of the rectum and colon.Chron's disease is a disease that lasts for a long time and causes severe irritation in your digestive tract.Psoriasis is a skin disease that gives you a dry, scaly rash.The study includes patient's data from the database who:Have at least 90 days of look-back periodHave any of these diseases (RA, UC, Crohn's disease, or Psoriasis) in the 90-day look back periodAre 15 years of age or older at the time of first dosingAll the patient's data included in this study would have received infliximab as intravenous (into veins) injection. | ||
| 650 | 2 | |a Arthritis | |
| 650 | 2 | |a Arthritis, Rheumatoid | |
| 650 | 2 | |a Crohn Disease | |
| 650 | 2 | |a Colitis | |
| 650 | 2 | |a Colitis, Ulcerative | |
| 650 | 2 | |a Psoriasis | |
| 650 | 2 | |a Ulcer | |
| 650 | 4 | |a Study Type: Observational | |
| 650 | 4 | |a Recruitment Status: Active, not recruiting | |
| 650 | 4 | |a 610 | |
| 773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2024) vom: 05. März |
| 773 | 1 | 8 | |g year:2024 |g day:05 |g month:03 |
| 856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT05796245 |z kostenfrei |3 Volltext |
| 912 | |a GBV_CTG | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 05 |c 03 | ||